Searching for a cure for heart failure

Cardiac regeneration: can science help the heart heal itself?

Read full story

Featured news

Presenting lupus and gout data at American College of Rheumatology meeting

AstraZeneca, along with MedImmune and Ardea Biosciences, is pleased to be presenting 13 abstracts at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting taking place in San Francisco, California, 6-11 November. The data highlight the progress of our inflammation and autoimmunity pipeline, with a focus on systemic lupus erythematosus (SLE), gout and rheumatoid arthritis, all diseases with serious unmet medical need.    

Among the key abstracts being presented are new data on anifrolumab, an investigational therapy for the treatment of SLE, a disease where only one new drug has been approved in over six decades. Anifrolumab blocks the activity of all Type I interferons, which could offer a new approach to treating lupus.  

We’re also presenting data for lesinurad for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor.

For more information, follow us on Twitter @AstraZeneca @MedImmune

Image: Artistic rendering of an antibody in inflammation and autoimmunity.


Join AstraZeneca

and help us deliver life-changing medicines

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.


The best science doesn't happen in isolation.

We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.

Page Atlas ID: 929087.011
Date of next review: November 2016